CHMFL-KIT-110固体分散体制备、理化性质及大鼠体内药代动力学

吴勇; 陈登俊; 汪潇; 孙宏张; 霍美蓉

doi:10.11665/j.issn.1000-5048.20200607

CHMFL-KIT-110固体分散体制备、理化性质及大鼠体内药代动力学

1.
中国药科大学药学院药剂系，南京 210009
2.
合肥合源药业有限公司，创新药物成药性评价安徽省重点实验室，合肥 230031

基金项目: 国家重大新药创制科技重大专项资助项目（No.2017ZX09101001）

计量
- 文章访问数: 0331
- HTML全文浏览量: 0
- PDF下载量: 0779
出版历程
- 收稿日期: 2020-05-11
- 修回日期: 2020-10-08
- 刊出日期: 2020-12-24

Preparation，physicochemical properties and pharmacokinetics in rats of CHMFL-KIT-110 solid dispersions

Funds: This work was supported by the National Science and Technology Major Project-Major New Drug Creation (No.2017ZX09101001)

摘要

摘要: 分别以聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物（Soluplus）、泊洛沙姆407（Poloxamer 407）、聚乙二醇6000（PEG 6000）、共聚维酮（Kollidon VA64）为载体，十二烷基硫酸钠（SLS）、吐温80（Tween 80）、聚氧乙烯氢化蓖麻油（Cremophor RH40）为增溶剂，采用溶剂法制备难溶性药物CHMFL-KIT-110的固体分散体，以动力学溶解度和溶液过饱和现象为指标优化固体分散体的处方。通过傅里叶变换红外光谱法、差热分析法、X射线粉末衍射法对成品进行物相表征，并考察其初步稳定性及大鼠体内药代动力学行为。结果表明，当CHMFL-KIT-110、Soluplus和SLS质量比为1∶4∶0.5时，CHMFL-KIT-110动力学溶解度显著提高且无药物晶体析出。CHMFL-KIT-110以无定形状态分散于载体中，在加速条件下（40 ℃、75%相对湿度）敞口放置30 d未发生结晶现象。大鼠体内药代动力学表明，CHMFL-KIT-110固体分散体的c_max和AUC_0→_t较原料药分别提高373.1倍和358.7倍。本研究为CHMFL-KIT-110的制剂开发和临床研究提供了理论基础。
- CHMFL-KIT-110 /
- 无定形固体分散体 /
- Soluplus /
- 溶解度 /
- 生物利用度
Abstract: Solid dispersions of the insoluble compound CHMFL-KIT-110 were prepared by solvent method with polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus),Poloxamer 407,PEG 6000,Copovidone (Kollidon VA64) as carriers and SLS,Tween 80,Cremophor RH40 as solubilizers. The optimal formulation was screened and obtained with dynamic solubilities and supersaturation performances as indexes. The final product was characterized by Fourier transform infrared (FT-IR),differential thermal analysis (DTA) and X-ray powder diffraction (XRPD). The stability and pharmacokinetic behavior in rats were also investigated. Results suggested that when the weight ratio of CHMFL-KIT-110/Soluplus/SLS was 1∶4∶0.5,dynamic solubility of the solid dispersions was significantly improved with no recrystallization. In the accelerated condition (40 °C,75% RH) for 30 days,CHMFL-KIT-110 in the solid dispersions was still amorphous with no crystal observed. The results of pharmacokinetics in rats showed that the c_max and AUC_0→_t of CHMFL-KIT-110 solid dispersions were 373.1 times and 358.7 times higher than those of free drugs,respectively. These results help to understand the formulation development and clinical practice of CHMFL-KIT-110.
- CHMFL-KIT-110 /
- amorphous solid dispersions /
- Soluplus /
- solubility /
- bioavailability

HTML全文

参考文献(8)

[1]	. J Med Chem，2016，59（8）：3964?3979.
[2]	Lee TW，Boersen NA，Hui HW，et al. Delivery of poorly soluble compounds by amorphous solid dispersions［J］. Curr Pharm Des，2014，20（3）：303?324.
[3]	Linn M，Collnot EM，L，Djuric D，et al. Soluplus^? as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo［J］. Eur J Pharm Sci，2012，45（3）：336?343.
[4]	Vasconcelos T，Sarmento B，Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs［J］. Drug Discov Today，2007，12（23-24）：1068?1075.
[5]	Lavra ZM，Santana DP，Ré MI. Solubility and dissolution performances of spray-dried solid dispersion of Efavirenz in Soluplus^?［J］. Drug Dev Ind Pharm，2017，43（1）：42?54.
[6]	Meng F，Gala U，Chauhan H. Classification of solid dispersions：correlation to （i） stability and solubility （ii） preparation and characterization techniques［J］. Drug Dev Ind Pharm，2015，41（9）：1401?1415.
[7]	Xia DN，Yu HZ，Tao JS，et al. Supersaturated polymeric micelles for oral cyclosporine A delivery：the role of Soluplus-sodium dodecyl sulfate complex［J］. Colloids Surf B Biointerfaces，2016，141：301?310.
[8]	Chen，JL，Chen YQ，Huang WC，et al. Bottom-up and top-down approaches to explore sodium dodecyl sulfate and soluplus on the crystallization inhibition and dissolution of felodipine extrudates［J］. J Pharm Sci，2018，107（9）：2366?2376.